文献速递心律失常心力衰竭与心肌病

基因检测在不明原因心脏骤停中的重要性

Importance of genetic testing in unexplained cardiac arrest.
PubMed 文献 · Eur Heart J · 2022-01-01

本研究纳入228例需体外除颤的UCA幸存者,采用全外显子组测序评估心血管病基因罕见变异。10%患者检出致病/可能致病变异,联合表型分析使「可解释」病例从9%升至18%。多数变异位于心肌病相关基因,支持在UCA幸存者中进行基因检测。

要点

  • UCA幸存者中全外显子组测序检出致病/可能致病变异比例为10%。
  • 联合表型与基因检测使可解释病例比例由9%提高至18%。
  • 多数致病变异位于心肌病相关基因,提示其致心律失常潜力。

核心结论

  • 基因检测可在10%的表观UCA幸存者中识别致病性变异。
  • 多数致病变异位于心肌病相关基因,支持在UCA幸存者中检测心律失常与心肌病基因。

研究设计与样本

  • 研究纳入来自心脏骤停幸存者保留射血分数注册研究的UCA幸存者228例,平均骤停年龄39±13岁。
  • 对患者行全外显子组测序并评估既往报道的心血管病基因中的罕见变异。

主要发现

  • 228例中男性占66%,欧洲血统占81%。
  • 基线高级临床检测后,21/228(9%)病例确定了心脏骤停的可能病因。
  • 全外显子组测序在23/228(10%)UCA幸存者中检出致病或可能致病变异。
  • 23个致病/可能致病变异中13个(57%)位于心肌病相关基因,且骤停时无心肌病诊断。

临床怎么用

  • 对UCA幸存者可考虑行全外显子组测序,检测范围包括心律失常与心肌病相关基因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Genetic testing is recommended in specific inherited heart diseases but its role remains unclear and it is not currently recommended in unexplained cardiac arrest (UCA). We sought to assess the yield and clinical utility of genetic testing in UCA using whole-exome sequencing (WES). METHODS AND RESULTS: Survivors of UCA requiring external defibrillation were included from the Cardiac Arrest Survivor with Preserved Ejection fraction Registry. Whole-exome sequencing was performed, followed by assessment of rare variants in previously reported cardiovascular disease genes. A total of 228 UCA survivors (mean age at arrest 39 ± 13 years) were included. The majority were males (66%) and of European ancestry (81%). Following advanced clinical testing at baseline, the likely aetiology of cardiac arrest was determined in 21/228 (9%) cases. Whole-exome sequencing identified a pathogenic or likely pathogenic (P/LP) variant in 23/228 (10%) of UCA survivors overall, increasing the proportion of 'explained' cases from 9% only following phenotyping to 18% when combining phenotyping with WES. Notably, 13 (57%) of the 23 P/LP variants identified were located in genes associated with cardiomyopathy, in the absence of a diagnosis of cardiomyopathy at the time of arrest. CONCLUSIONS: Genetic testing identifies a disease-causing variant in 10% of apparent UCA survivors. The majority of disease-causing variants was located in cardiomyopathy-associated genes, highlighting the arrhythmogenic potential of such variants in the absence of an overt cardiomyopathy diagnosis. The present study supports the use of genetic testing including assessment of arrhythmia and cardiomyopathy genes in survivors of UCA.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Grondin S, Davies B, Cadrin-Tourigny J, et al. Importance of genetic testing in unexplained cardiac arrest. Eur Heart J. 2022. PMID: 35352813. doi:10.1093/eurheartj/ehac145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。